日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer's Disease: Synthesis of Evidence from Observational and Interventional Trials

磁共振成像中海马萎缩作为早期症状性阿尔茨海默病临床获益和神经退行性变的替代标志物:观察性和干预性试验证据的综合分析

Abushakra, Susan; Doraiswamy, P Murali; Hey, John A; Tosun, Duygu; Barkhof, Frederik; Barakos, Jerome; Petrella, Jeffrey; Kesslak, J Patrick; Power, Aidan; Sabbagh, Marwan; Porsteinsson, Anton; Cohen, Sharon; Gauthier, Serge; Ritchie, Craig; Watson, David; McSweeney, Emer; Boada, Merce; Liang, Earvin; Bracoud, Luc; McLaine, Rosalind; Flint, Susan; Schaefer, Jean F; Yu, Jeremy; Bray, Margaret; Hendrix, Suzanne; Dickson, Sam; Durrant, Abe; Albayrak, Adem; Tolar, Martin

Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial

口服缬氨曲普罗酯治疗APOEε4/ε4纯合子早期阿尔茨海默病患者的临床疗效、安全性和影像学效应:III期随机、双盲、安慰剂对照、78周APOLLOE4试验结果

Abushakra, Susan; Power, Aidan; Watson, David; Porsteinsson, Anton; Sabbagh, Marwan; MacSweeney, Emer; Cohen, Sharon; Boada Rovira, Mercè; Doraiswamy, P Murali; Liang, Earvin; Flint, Susan; Kesslak, J Patrick; McLaine, Rosalind; Albayrak, Adem; Schaefer, Jean; Yu, Jeremy; Tolar, Luke; Dickson, Sam; Hey, John A; Tolar, Martin

Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer's Disease

一项针对携带APOE4基因且患有早期阿尔茨海默病的患者开展的为期2年的II期临床试验中,口服ALZ-801/Valiltramiprosate的临床药代动力学研究

Hey, John A; Yu, Jeremy Y; Abushakra, Susan; Schaefer, Jean F; Power, Aidan; Kesslak, Pat; Paul, Jijo; Tolar, Martin

Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease

口服ALZ-801/Valiltramiprosate对血浆生物标志物、脑海马体积和认知功能的影响:一项针对携带APOE4基因且患有早期阿尔茨海默病患者的为期2年的单臂、开放标签II期临床试验结果

Hey, John A; Abushakra, Susan; Blennow, Kaj; Reiman, Eric M; Hort, Jakub; Prins, Niels D; Sheardova, Katerina; Kesslak, Patrick; Shen, Larry; Zhu, Xinyi; Albayrak, Adem; Paul, Jijo; Schaefer, Jean F; Power, Aidan; Tolar, Martin

Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer's Disease Using Quantitative Systems Pharmacology Model

利用定量系统药理学模型分析一项为期两年的 II 期临床试验中,口服 ALZ-801/Valiltramiprosate 对携带 APOE4 基因的早期阿尔茨海默病患者的脑脊液、血浆 β-淀粉样蛋白生物标志物和认知功能的影响

Hey, John A; Yu, Jeremy Y; Abushakra, Susan; Schaefer, Jean F; Power, Aidan; Kesslak, Patrick; Tolar, Martin

APOLLOE4 Phase 3 study of oral ALZ-801/valiltramiprosate in APOE ε4/ε4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristics

APOLLOE4 3期研究:口服ALZ-801/valiltramiprosate治疗APOE ε4/ε4纯合子早期阿尔茨海默病患者的疗效:试验设计和基线特征

Abushakra, Susan; Porsteinsson, Anton P; Sabbagh, Marwan; Watson, David; Power, Aidan; Liang, Earvin; MacSweeney, Emer; Boada, Merce; Flint, Susan; McLaine, Rosalind; Kesslak, J Patrick; Hey, John A; Tolar, Martin

The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention

阿尔茨海默病和其他神经退行性疾病的单一毒素起源为靶向治疗和预防提供了可能

Tolar, Martin; Hey, John A; Power, Aidan; Abushakra, Susan

Plasma Biomarkers, Hippocampal Volume and Cognitive Effects of Oral ALZ‐801: The Phase 2 Biomarker Study and its Long‐Term Extension in APOE4 Carriers with Early Alzheimer’s Disease

口服ALZ-801对血浆生物标志物、海马体积和认知功能的影响:APOE4携带者早期阿尔茨海默病患者的II期生物标志物研究及其长期扩展研究

Haidari, Fatemeh; Abiri, Behnaz; Iravani, Masood; Razavi, Seyed-Mohsen; Sarbakhsh, Parvin; Ahmadi-Angali, Kambiz; Vafa, Mohammadreza; Huang, Haochun; Li, Zexu; Young, Christina B; Smith, Viktorija; Ang, Ting Fang Alvin; Kolachalama, Vijaya B; Au, Rhoda; Chen, Jinying; Kuchenbecker, Lindsey A; Tipton, Philip W; Brier, Matthew R; Satyadev, Nihal; Piura, Yoav D; Dunham, S Richard; O'Bryant, Sid E; Graff‐Radford, Neill R; Day, Gregory S; Windham, B Gwen; Blackshear, Chad T; Ali, Farwa; Knopman, David S; Walker, Keenan A; Pike, James Russell; Lu, Yifei; Mosley, Thomas H; Palta, Priya; Griswold, Michael E; Abushakra, Susan; Hey, John A; Blennow, Kaj; Hort, Jakub; Prins, Niels D; Kesslak, Patrick; Pak, Winnie; Shen, Larry; Zhu, Xinyi; Li, Caiyan; Albayrak, Adem; Bracoud, Luc; Suhy, Joyce; Power, Aidan; Tolar, Martin

Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval

Aducanumab、gantenerumab、BAN2401 和 ALZ-801——首批有望近期获批的阿尔茨海默病淀粉样蛋白靶向药物

Martin Tolar, Susan Abushakra, John A Hey, Anton Porsteinsson, Marwan Sabbagh

APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline

携带APOE ε4/ε4纯合基因的早期阿尔茨海默病患者表现出海马萎缩加速和皮质变薄,且与认知能力下降相关。

Abushakra, Susan; Porsteinsson, Anton P; Sabbagh, Marwan; Bracoud, Luc; Schaerer, Joel; Power, Aidan; Hey, John A; Scott, David; Suhy, Joyce; Tolar, Martin